Skip to main content

This job has expired

You will need to login before you can apply for a job.

Pricing, Contracting and Managed Markets Finance | Intern

Employer
Scilex Holding Company
Location
Summit, NJ
Start date
Feb 3, 2024

View more

Discipline
Administration, Finance
Required Education
Bachelors Degree
Position Type
Part time

Job Details

Salary Range: $17 - $21 per hour 

The pay range for this position is expected to be between $17 - $21 per hour; however, the base pay offered may vary depending on multiple individualized factors, including market location, job-related knowledge, skills and experience.  The total compensation package for this position also includes medical benefits, 401(k) eligibility, vacation, sick time, and parental leave.  Additional details of participation in these benefit plans will be provided if an employee receives an offer of employment.    

If hired, employee will be in an “at-will position” and the Company reserves the right to modify base salary (as well as any other payment or compensation program) at any time, including reasons related to individual performance, Company or individual department/team performance, and market factors.   

Scilex Holding Company’s pay range data is provided in accordance with local state pay transparency regulations.  Scilex Holding Company may post different minimum wage ranges for permanent residency petitions pursuant to US Department of Labor requirements.     

Scilex Holding Company is committed to equal employment opportunities, and a workplace that embraces diversity and inclusion for qualified individuals of all backgrounds.   

About Scilex 

SCILEX HOLDING COMPANY (Nasdaq: SCLX, “Scilex”), is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain.  We are uncompromising in our focus to become the global pain management leader committed to social, environmental, economic, and ethical principles to responsibly develop pharmaceutical products to maximize quality of life.

The company’s lead product ZTlido® (lidocaine topical system) 1.8%, is a marketed prescription lidocaine topical product approved by the U.S. Food and Drug Administration for the relief of pain associated with Post-Herpetic Neuralgia (PHN), which is a form of post-shingles nerve pain. ZTlido® possesses novel delivery and adhesion technology designed to address many of the limitations of current prescription lidocaine patches by providing significantly improved adhesion and continuous pain relief throughout the 12-hour administration period.  Click here for ZTLido’s Important Safety Information and US Prescribing Information.

We have acquired two FDA approved non-opioid pain products, GLOPERBA and ELYXYBTM, for the treatment of gout in adults and oral solution for the acute treatment of migraine, with or without aura, in adults. We launched ELYXYBTM in the U.S. in April 2023 and are planning to commercialize GLOPERBA in 2024.

Our three product candidates are (i) SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (“SEMDEXATM”), a Phase 3, novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica and has received Fast Track Status from the FDA. Currently there is no FDA approved non-opioid epidural injection to treat lumbosacral radicular pain, or sciatica; (ii) SP-103 (lidocaine topical system) 5.4%, (“SP-103”), a Phase 2, next-generation, triple-strength formulation of ZTlido, for the treatment of low back pain (“LBP”) and has received Fast Track Status from the FDA; and (iii) SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) (“SP-104”), a novel low-dose delayed-release naltrexone hydrochloride being developed for the treatment of fibromyalgia.  If these product candidates are approved by the FDA, we believe each of them could become the treatment option for their respective indications in the United States.

SCILEX is committed to harnessing the power of revolutionary delivery technologies designed to safely and effectively provide therapies to those who need them the most. Scilex Pharmaceuticals and Semnur Pharmaceuticals are wholly-owned subsidiaries of Scilex Holding Company.

If you’re a high-energy, compassionate, and collaborative individual with a strong desire to make a difference in patient’s lives, we encourage you to consider joining the Scilex Holding team! 

Role and Responsibilities

Support Sr. Director, Pricing and Contracting with financial, business and compliance related functions including:

  • Chargebacks data validation and reporting
  • Rebate data validation, reporting and analysis
  • Document support for internal and external audits
  • Other pricing, contracting and managed markets finance support, as required.

Qualifications and Education Requirements

  • College/University student who has completed > 50% of requirements for degree or recent College/University graduate
  • Preferred Finance, Accounting or Business Administration related major
  • Data analysis and financial analysis and/or accounting experience
  • Secondary data and information research experience

Preferred Skills:

  • Proficient with Microsoft applications (Advanced Excel, WORD and PowerPoint)
  • Detail oriented and analytical
  • Ability to work independently with limited supervision and as a team member
  • Driven to excel and learn new skills
  • High degree of intellectual curiosity

    Company

    SCILEX HOLDING COMPANY (Nasdaq: SCLX, “Scilex”), majority-owned by Sorrento, is dedicated to the development and commercialization of non-opioid pain management products. We are uncompromising in our focus to become the global pain management leader committed to social, environmental, economic, and ethical principles to responsibly develop pharmaceutical products to maximize quality of life.

    The company’s lead product ZTlido® (lidocaine topical system) 1.8%, is a branded prescription lidocaine topical product approved by the U.S. Food and Drug Administration for the relief of pain associated with Post-Herpetic Neuralgia (PHN), which is a form of post-shingles nerve pain.

    Scilex’s SP-102 (10 mg dexamethasone sodium phosphate viscous gel injection), or SEMDEXA™, for the treatment of Lumbar Radicular Pain has completed enrollment in a Phase III clinical trial and has received Fast Track Status from the FDA. If approved by the FDA, the company expects SP-102 to be the first FDA-approved non-opioid epidural injection to treat lumbosacral radicular pain, or sciatica, with the potential to replace 10 to 11 million off-label epidural steroid injections administered each year in the US.

    SCILEX is committed to harnessing the power of revolutionary delivery technologies designed to safely and effectively provide therapies to those who need them the most.

    Scilex Pharmaceuticals and Semnur Pharmaceuticals are wholly-owned subsidiaries of Scilex Holding Company.

    Company info
    Website
    Phone
    (650) 516-4310
    Location
    960 San Antonio Road
    Palo Alto
    California
    94303
    US

    Get job alerts

    Create a job alert and receive personalized job recommendations straight to your inbox.

    Create alert